ValiRx (LSE:VAL) FCF Yield % : -72.22 (As of Jun. 26, 2025)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ValiRx's Trailing 12-Month Free Cash Flow is £-1.62 Mil, and Market Cap is £2.25 Mil. Therefore, ValiRx's FCF Yield % for today is -72.22%.

The historical rank and industry rank for ValiRx's FCF Yield % or its related term are showing as below:

LSE:VAL' s FCF Yield % Range Over the Past 10 Years
Min: -285741.39 Med: -5019.51 Max: -31.14
Current: -72.22

During the past 13 years, the highest FCF Yield % of ValiRx was -31.14%. The lowest was -285741.39%. And the median was -5019.51%.

LSE:VAL's FCF Yield % is ranked worse than
80.61% of 1501 companies
in the Biotechnology industry
Industry Median: -13.56 vs LSE:VAL: -72.22

ValiRx's FCF Margin % for the quarter that ended in Dec. 2024 was -1,408.00%.

ValiRx FCF Yield % Historical Data

The historical data trend for ValiRx's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx FCF Yield % Chart

ValiRx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Yield %

Get a 7-Day Free Trial

-15.84

-5.35

-13.56

-34.42

-55.94

ValiRx Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Yield %	Get a 7-Day Free Trial															-19.49	-37.93	-22.23	-44.04	-48.53

Competitive Comparison of ValiRx's FCF Yield %

For the Biotechnology subindustry, ValiRx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ValiRx's FCF Yield % falls into.

Save Embed

;

Save Embed

;

ValiRx FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ValiRx's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1.623	/	2.90120475
	=	-55.94%

ValiRx's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.704	*	2	/	2.90120475
	=	-48.53%

ValiRx FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

ValiRx FCF Yield % Related Terms

Thank you for viewing the detailed overview of ValiRx's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.